AI assistant
BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2014
Mar 7, 2014
31868_dirs_2014-03-07_ed99b5cf-eaa9-4645-a338-7cd21a0d8f62.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2014-03-01
Reporting Person: STAAB THOMAS R II (Senior Vice President and CFO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-03-01 | Common Stock | F | 461 | $11.69 | Disposed | 126616 | Direct |
| 2014-03-04 | Common Stock | M | 3000 | $4.73 | Acquired | 129616 | Direct |
| 2014-03-04 | Common Stock | S | 3000 | $12.69 | Disposed | 126616 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-03-04 | Emp. Stock Option (Right to Buy) | $4.73 | M | 3000 | Disposed | 2022-03-01 | Common Stock (3000) | Direct |
Footnotes
F1: Shares withheld by BioCryst Pharmaceuticals, Inc. upon the vesting of restricted stock to satisfy the reporting person's tax withholding obligations.
F2: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.69 to $12.70. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.